Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Tuesday. The brokerage issued a sell rating on the stock.

Oragenics Trading Down 0.9 %

OGEN opened at $0.28 on Tuesday. Oragenics has a 12-month low of $0.25 and a 12-month high of $3.43. The firm has a market capitalization of $3.39 million, a PE ratio of -0.04 and a beta of 0.85. The firm has a 50 day moving average of $0.31 and a two-hundred day moving average of $0.41.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.